This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Thanatophoric dysplasia

Authoring team

Thanatophoric dysplasia (TD) is the most common neonatal lethal skeletal dysplasia.

  • incidence is approximately one per 20,000 live births

  • most frequent lethal skeletal dysplasia

  • caused by the FGFR3 gene mutation

  • although ultraonography has been used for prenatal diagnosis of TD, occasionally TD fetuses in utero cannot be clearly distinguished from other osteochondrodysplasias

  • term is derived from the Greek word 'thanatophoros,' which means 'death bearing'
    • most common lethal skeletal disorder

    • two main forms of TD based on the bone deformity pattern
      • Type-1 TD is characterized by short and curved femurs with a telephone-receiver-like appearance, together with very flat vertebral bodies
        • rarely associated with a cloverleaf skull deformity
      • Type-2 TD has straighter femora, but they are just as short
        • characterized by flatter vertebral bodies and is almost always associated with a cloverleaf skull

    • prenatal diagnosis of TD by ultrasonography has been based on these characteristic shortened limbs or other skeletal defects consistent with TD

Affected individuals die within hours of birth, usually from respiratory failure

  • affected neonate usually dies shortly after birth owing to profound pulmonary hypoplasia

Reference:


Create an account to add page annotations

Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.